These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 12166927)

  • 21. The nuclear hormone receptor farnesoid X receptor (FXR) is activated by androsterone.
    Wang S; Lai K; Moy FJ; Bhat A; Hartman HB; Evans MJ
    Endocrinology; 2006 Sep; 147(9):4025-33. PubMed ID: 16675527
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The farnesoid X receptor induces very low density lipoprotein receptor gene expression.
    Sirvent A; Claudel T; Martin G; Brozek J; Kosykh V; Darteil R; Hum DW; Fruchart JC; Staels B
    FEBS Lett; 2004 May; 566(1-3):173-7. PubMed ID: 15147890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Beneficial effect of farnesoid X receptor activation on metabolism in a diabetic rat model.
    Zhang HM; Wang X; Wu ZH; Liu HL; Chen W; Zhang ZZ; Chen D; Zeng TS
    Mol Med Rep; 2016 Mar; 13(3):2135-42. PubMed ID: 26782298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy.
    Xing X; Burgermeister E; Geisler F; Einwächter H; Fan L; Hiber M; Rauser S; Walch A; Röcken C; Ebeling M; Wright MB; Schmid RM; Ebert MP
    Hepatology; 2009 Mar; 49(3):979-88. PubMed ID: 19072826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes.
    Langhi C; Le May C; Kourimate S; Caron S; Staels B; Krempf M; Costet P; Cariou B
    FEBS Lett; 2008 Mar; 582(6):949-55. PubMed ID: 18298956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 1,25-dihydroxyvitamin D3 and its receptor inhibit the chenodeoxycholic acid-dependent transactivation by farnesoid X receptor.
    Honjo Y; Sasaki S; Kobayashi Y; Misawa H; Nakamura H
    J Endocrinol; 2006 Mar; 188(3):635-43. PubMed ID: 16522742
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Farnesoid X receptor induces GLUT4 expression through FXR response element in the GLUT4 promoter.
    Shen H; Zhang Y; Ding H; Wang X; Chen L; Jiang H; Shen X
    Cell Physiol Biochem; 2008; 22(1-4):1-14. PubMed ID: 18769028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo.
    Rizzo G; Disante M; Mencarelli A; Renga B; Gioiello A; Pellicciari R; Fiorucci S
    Mol Pharmacol; 2006 Oct; 70(4):1164-73. PubMed ID: 16778009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, characterization, and receptor interaction profiles of enantiomeric bile acids.
    Katona BW; Cummins CL; Ferguson AD; Li T; Schmidt DR; Mangelsdorf DJ; Covey DF
    J Med Chem; 2007 Nov; 50(24):6048-58. PubMed ID: 17963371
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats.
    Verbeke L; Farre R; Verbinnen B; Covens K; Vanuytsel T; Verhaegen J; Komuta M; Roskams T; Chatterjee S; Annaert P; Vander Elst I; Windmolders P; Trebicka J; Nevens F; Laleman W
    Am J Pathol; 2015 Feb; 185(2):409-19. PubMed ID: 25592258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism.
    Gohda K; Iguchi Y; Masuda A; Fujimori K; Yamashita Y; Teno N
    Bioorg Med Chem Lett; 2021 Jun; 41():128026. PubMed ID: 33839252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Farnesoid X receptor activation by chenodeoxycholic acid induces detoxifying enzymes through AMP-activated protein kinase and extracellular signal-regulated kinase 1/2-mediated phosphorylation of CCAAT/enhancer binding protein β.
    Noh K; Kim YM; Kim YW; Kim SG
    Drug Metab Dispos; 2011 Aug; 39(8):1451-9. PubMed ID: 21596890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease.
    Wu W; Zhu B; Peng X; Zhou M; Jia D; Gu J
    Biochem Biophys Res Commun; 2014 Jan; 443(1):68-73. PubMed ID: 24269813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and Optimization of Non-bile Acid FXR Agonists as Preclinical Candidates for the Treatment of Nonalcoholic Steatohepatitis.
    Li J; Liu M; Li Y; Sun DD; Shu Z; Tan Q; Guo S; Xie R; Gao L; Ru H; Zang Y; Liu H; Li J; Zhou Y
    J Med Chem; 2020 Nov; 63(21):12748-12772. PubMed ID: 32991173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. UDCA and CDCA alleviate 17α-ethinylestradiol-induced cholestasis through PKA-AMPK pathways in rats.
    Li X; Yuan Z; Liu R; Hassan HM; Yang H; Sun R; Zhang L; Jiang Z
    Toxicol Appl Pharmacol; 2016 Nov; 311():12-25. PubMed ID: 27743861
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disruption of TFGβ-SMAD3 pathway by the nuclear receptor SHP mediates the antifibrotic activities of BAR704, a novel highly selective FXR ligand.
    Carino A; Biagioli M; Marchianò S; Scarpelli P; Zampella A; Limongelli V; Fiorucci S
    Pharmacol Res; 2018 May; 131():17-31. PubMed ID: 29530598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis.
    Fiorucci S; Rizzo G; Antonelli E; Renga B; Mencarelli A; Riccardi L; Orlandi S; Pruzanski M; Morelli A; Pellicciari R
    J Pharmacol Exp Ther; 2005 Aug; 314(2):584-95. PubMed ID: 15860571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR.
    Downes M; Verdecia MA; Roecker AJ; Hughes R; Hogenesch JB; Kast-Woelbern HR; Bowman ME; Ferrer JL; Anisfeld AM; Edwards PA; Rosenfeld JM; Alvarez JG; Noel JP; Nicolaou KC; Evans RM
    Mol Cell; 2003 Apr; 11(4):1079-92. PubMed ID: 12718892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low retinol levels differentially modulate bile salt-induced expression of human and mouse hepatic bile salt transporters.
    Hoeke MO; Plass JR; Heegsma J; Geuken M; van Rijsbergen D; Baller JF; Kuipers F; Moshage H; Jansen PL; Faber KN
    Hepatology; 2009 Jan; 49(1):151-9. PubMed ID: 19111018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro farnesoid X receptor ligand sensor assay using surface plasmon resonance and based on ligand-induced coactivator association.
    Fujino T; Sato Y; Une M; Kanayasu-Toyoda T; Yamaguchi T; Shudo K; Inoue K; Nishimaki-Mogami T
    J Steroid Biochem Mol Biol; 2003 Dec; 87(4-5):247-52. PubMed ID: 14698205
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.